# Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes

> **NCT00503880** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Nebraska** · enrollment: 2 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** clofarabine
- **DRUG:** cytarabine
- **GENETIC:** microarray analysis
- **PROCEDURE:** biopsy

## Key facts

- **NCT ID:** NCT00503880
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-05-07
- **Primary completion:** 2009-10-13
- **Final completion:** 2009-10-13
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Genzyme discontinued Funding
- **Last updated:** 2023-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00503880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00503880, "Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT00503880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*